Changes and significance of interleukin-33,tumor necrosis factor-αand C reaction protein levels in patients with rheumatoid arthritis

Hong Y S, Moon S J, Joo Y B. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis [J]. Journal of Korean Medical Science, 2011(9):1132.

Nishina N, Kaneko Y, Kameda H. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis:a potential biomarker for radiographic progression [J]. Clinical Rheumatology, 2013.

Gui M, Zhang H, Zhong K. Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis [J]. Asian PacJ Allergy Immunol, 2013(1):73.

Olofsson T, Petersson I F, Eriksson J K. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort [J]. Annals of the Rheumatic Diseases, 2013.

Shono E. Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis [J]. Drug Development Research, 2013(1):95.

Kageyama Y, Torikai E, Tsujimura K. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis:the effect of etanercept on the serum levels of IL-33 [J]. Modern Rheumatology, 2012(1):89.

Barksby H E, Lea S R, Preshaw P M. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [J]. Clinical and Experimental Immunology, 2007(2):217.

Madsen O R. Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biolcgical agents in the daily clinic [J]. Journal of Rheumatology, 2013(4):379.

Gruszcwska E, Chludzinska A, Chrostek L. Carbohydrate-deficient transferrin depends on disease activity in rheumatoid arthritis and systemic.sclerosis [J]. Scandinavian Journal of Rheumatology, 2013(3):203.

Ndongo S, Pouye A, Lekpa F K. Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa:outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis [J]. Med Sante Trop, 2012(4):385.

Gerli R, Lunardi C, Bocci E B. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30 [J]. Journal of Rheumatology, 2008(1):14.

Rezaieyazdi Z, Afshari J T, Sandooghi M. Tumour necrosis factor a-308 promoter polymorphism in patients with rheumatoid arthritis [J]. Rheumatology International, 2007(2):189.

Aloush V, George J, Elkayam O. Decreased levels of CCR3 in CD4 + lymphocytes of rheumatoid arthritis patients [J]. Clinical and Experimental Rheumatology, 2010(4):462.

Capria A, De Nardo D, Baffetti F R. Long-term antiTNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis:the biological coherence between synovial and endothelial inflammation [J]. International Journal of Immunopathology and Pharmacology, 2010(1):255.

El-Tantawy A M, El-Sayed A E, Kora B A. Psychiatric morbidity associated with some cytokines (IL 1beta, IL-12, IL-18 and TNF-alpha) among rheumatoid arthritis patients [J]. Egyptian Journal of Immunology, 2008(1):1.